{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:35:44Z","timestamp":1776735344108,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Innovation Drug and Medical Device Product Application Demonstration Project","award":["24SF1905500"],"award-info":[{"award-number":["24SF1905500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15822-9","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:06:40Z","timestamp":1773227200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy of HAIC combined with TACE in patients with unresectable intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Juncheng","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoqiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuran","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bufu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"2","key":"15822_CR1","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"15822_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","volume":"28","author":"R El-Diwany","year":"2019","unstructured":"El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin North Am. 2019;28(4):587\u201399.","journal-title":"Surg Oncol Clin North Am"},{"issue":"9","key":"15822_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102223","volume":"47","author":"A Pascale","year":"2023","unstructured":"Pascale A, Rosmorduc O, Duclos-Vall\u00e9e JC. New epidemiologic trends in cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2023;47(9):102223.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"15822_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 2016;21(5):594\u20139.","journal-title":"Oncologist"},{"key":"15822_CR5","doi-asserted-by":"crossref","unstructured":"Benson AB, D\u2019Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, et al. NCCN guidelines\u00ae insights: Biliary tract cancers, version 2.2023: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2023 July 1;21(7):694\u2013704.","DOI":"10.6004\/jnccn.2023.0035"},{"key":"15822_CR6","doi-asserted-by":"crossref","unstructured":"Patel S, Hasanain A, Fang A, Khavandi MM, Mathias T, Cohen EI, et al. Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2024 Sept;18(9):505\u201319.","DOI":"10.1080\/17474124.2024.2402358"},{"issue":"1150","key":"15822_CR7","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20230079","volume":"96","author":"Z Ning","year":"2023","unstructured":"Ning Z, Xie L, Yan X, Hua Y, Shi W, Lin J, et al. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol. 2023;96(1150):20230079.","journal-title":"Br J Radiol"},{"key":"15822_CR8","first-page":"9680933","volume":"2022","author":"P Huang","year":"2022","unstructured":"Huang P, Huang X, Zhou Y, Yang G, Sun Q, Shi G, et al. The efficacy and safety of hepatic arterial infusion chemotherapy based on FOLFIRI for advanced intrahepatic cholangiocarcinoma as second-line and successive treatment: A real-world study. Can J Gastroenterol. 2022;2022:9680933.","journal-title":"Can J Gastroenterol"},{"issue":"5","key":"15822_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Groot Koerkamp B, Do RKG, G\u00f6nen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758\u201365.","journal-title":"Cancer"},{"issue":"4","key":"15822_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11604-021-01212-7","volume":"40","author":"JZ Wu","year":"2022","unstructured":"Wu JZ, Li CL, Shi HB, Liu S, Yang W, Zhou WZ. Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study. Jpn J Radiol. 2022;40(4):396\u2013403.","journal-title":"Jpn J Radiol"},{"key":"15822_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235724","volume":"14","author":"Z Wei","year":"2023","unstructured":"Wei Z, Wang Y, Wu B, Liu Y, Wang Y, Ren Z, et al. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma. Front Immunol. 2023;14:1235724.","journal-title":"Front Immunol"},{"issue":"5","key":"15822_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer. 2023;12(5):405\u201344.","journal-title":"Liver Cancer"},{"issue":"01","key":"15822_CR13","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):052\u201360.","journal-title":"Semin Liver Dis"},{"issue":"8","key":"15822_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"15822_CR15","doi-asserted-by":"crossref","unstructured":"Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L et al. SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2025;43(5):536\u2013544.","DOI":"10.1200\/JCO-24-01383"},{"issue":"3","key":"15822_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.21.00679","volume":"40","author":"JM Phelip","year":"2022","unstructured":"Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, et al. Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): A randomized phase II study. J Clin Oncol. 2022 Jan 20;40(3):262\u201371.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15822_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11547-024-01781-3","volume":"129","author":"N Jiang","year":"2024","unstructured":"Jiang N, Zhang Z, Yin X, Qiu H, Yan W, Hao Y, et al. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective cohort study. Radiol Med. 2024;129(4):631\u201342.","journal-title":"Radiol Med"},{"key":"15822_CR18","doi-asserted-by":"crossref","unstructured":"Massani M, Bonariol L, Stecca T. Hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma, a comprehensive review. J Clin Med. 2021 June 9;10(12):2552.","DOI":"10.3390\/jcm10122552"},{"key":"15822_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1234342","volume":"14","author":"Z Yang","year":"2023","unstructured":"Yang Z, Fu Y, Wu W, Hu Z, Pan Y, Wang J, et al. Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Front Pharmacol. 2023;14:1234342.","journal-title":"Front Pharmacol"},{"issue":"10","key":"15822_CR20","doi-asserted-by":"publisher","first-page":"6942","DOI":"10.1097\/JS9.0000000000002890","volume":"111","author":"J Wan","year":"2025","unstructured":"Wan J, Tang B, Zhang W, Zhou Y, Jin C, Yu C, et al. Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study. Int J Surg. 2025;111(10):6942\u201360.","journal-title":"Int J Surg"},{"issue":"5","key":"15822_CR21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023 May 1;109(5):1222\u201330.","journal-title":"Int J Surg"},{"issue":"4","key":"15822_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00280-015-2704-0","volume":"75","author":"H Ishiwatari","year":"2015","unstructured":"Ishiwatari H, Hayashi T, Yoshida M, Ono M, Sato T, Miyanishi K, et al. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. Cancer Chemother Pharmacol. 2015 Apr 1;75(4):805\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"15822_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.critrevonc.2008.09.008","volume":"69","author":"S Mosconi","year":"2009","unstructured":"Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69(3):259\u201370.","journal-title":"Crit Rev Oncol Hematol"},{"key":"15822_CR24","doi-asserted-by":"crossref","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019 July 1;5(7):953\u201360.","DOI":"10.1001\/jamaoncol.2019.0250"},{"key":"15822_CR25","doi-asserted-by":"publisher","first-page":"111642","DOI":"10.1016\/j.intimp.2024.111642","volume":"129","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhu C, Zhang N, Zhang L, Wang S, Xun Z, et al. Lenvatinib combined with PD-1 inhibitor plus gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. Int Immunopharmacol. 2024 Mar 10;129:111642.","journal-title":"Int Immunopharmacol"},{"key":"15822_CR26","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2024.01286","author":"Z Sun","year":"2024","unstructured":"Sun Z, Xu H, Yang L, Wang X, Shu B, Yang M, et al. mFOLFOX-HAIC+lenvatinib\u2009+\u2009PD-1 inhibitors versus GC\/GS\/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: a single-center retrospective cohort study. BST. 2024. https:\/\/doi.org\/10.5582\/bst.2024.01286.","journal-title":"BST"},{"issue":"10","key":"15822_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1470-2045(25)00376-6","volume":"26","author":"G Shi","year":"2025","unstructured":"Shi G, Huang X, Li X, Liang F, Gao Q, Zhang D, et al. Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study. Lancet Oncol. 2025;26(10):1334\u201345.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15822_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023 Mar 17;8(1):106.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"15822_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00270-020-02661-9","volume":"44","author":"K Zheng","year":"2021","unstructured":"Zheng K, Wang X, Cao G, Xu L, Zhu X, Fu L, et al. Hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced gallbladder cancer. Cardiovasc Intervent Radiol. 2021;44(2):271\u201380.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"15822_CR30","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1245\/s10434-014-3766-7","volume":"21","author":"K Kasai","year":"2014","unstructured":"Kasai K, Kooka Y, Suzuki Y, Suzuki A, Oikawa T, Ushio A, et al. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon \u03b1-2b for advanced intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2014;21(11):3638\u201345.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"15822_CR31","doi-asserted-by":"publisher","first-page":"e0266707","DOI":"10.1371\/journal.pone.0266707","volume":"17","author":"M Ishii","year":"2022","unstructured":"Ishii M, Itano O, Morinaga J, Shirakawa H, Itano S. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PLoS One. 2022;17(4):e0266707.","journal-title":"PLoS One"},{"issue":"2","key":"15822_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181\u20138.","journal-title":"Lancet Oncol"},{"issue":"30","key":"15822_CR33","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1200\/JCO.2011.37.9651","volume":"29","author":"GK Abou-Alfa","year":"2011","unstructured":"Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29(30):3949\u201352.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15822_CR34","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1478-3231.2012.02783.x","volume":"32","author":"J Xu","year":"2012","unstructured":"Xu J, Igarashi S, Sasaki M, Matsubara T, Yoneda N, Kozaka K, et al. Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int. 2012;32(7):1156\u201364.","journal-title":"Liver Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15822-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15822-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15822-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:36:55Z","timestamp":1776731815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15822-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15822"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15822-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Zhongshan Hospital Research Ethics Committee (B2025-017) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the clinical details and clinical images was obtained from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"503"}}